AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

10 Nov 2023 08:00:10 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 16:37:36 By Nasdaq GlobeNewswire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

31 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update

09 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

20 Sep 2023 09:04:50 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

11 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

23 Aug 2023 08:00:42 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 16:01:06 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

02 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

25 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

06 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

29 Jun 2023 08:42:55 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

31 May 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

02 May 2023 16:31:30 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

26 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

20 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

18 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

29 Mar 2023 08:30:00 By Nasdaq GlobeNewswire